Pharmacokinetic profiles of EpCAM X CLDN3 BsADC 3 and total antibody in non-tumor bearing mice were evaluated after single intravenous administration of BsADC 3 and the IgG-ADC at doses of 10 mg/kg (Fig. 7A). Here, CLDN3 is linked to neoplasm.